BACKGROUND Peripheral artery disease (PAD) is associated with heightened ischemic and bleeding risk in patients
, the combination of aspirin and a P2Y 12 inhibitor in patients with PAD undergoing lower extremity bypass surgery did not reduce a broad composite of cardiovascular and limb endpoints (7) . However, larger studies evaluating the combination of aspirin and clopidogrel have shown trends of benefit for reducing MACE in patients with symptomatic vascular disease, including those with PAD (8, 9) . More recently, the addition of a PAR-1 antagonist, vorapaxar, was shown to reduce the risk of MACE in patients with prior MI or PAD but increase GUSTO (Global Use of Strategies to Open Occluded Arteries) moderate or severe bleeding (10) . In addition to reducing MACE, vorapaxar was shown to reduce limb morbidity, including acute limb ischemia (ALI) and peripheral revascularization procedures, when added to aspirin and/or clopidogrel (11, 12) . These findings highlight the potential of grant support from AstraZeneca. Dr. Bonaca has received consulting fees from AstraZeneca, Merck, Bayer, and Roche Diagnostics. Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi, and The Medicines Company; has received royalties from Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); is a site coinvestigator for Biotronik, Boston Scientific, and St. Jude Medical; is a trustee of the American College of Cardiology; and has performed unfunded research for FlowCo, PLx Pharma, and Takeda. Dr. Storey has received grants, personal fees, and travel support from AstraZeneca; and has received personal/consultancy fees from Aspen, PlaqueTec, Correvio, The Medicines Company, Medscape, and Thermo Fisher Scientific. Dr. Steg has received research grants from Merck, Sanofi, and Servier; and has served as a consultant or speaker for Amarin, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, CSL Behring, Daiichi-Sankyo-Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Sanofi, Servier, and The Medicines Company. Dr. Cohen has received grants and personal fees from AstraZeneca during the conduct of the study; outside of this study he has received personal fees from Merck, Janssen, Maquet, malpractice attorneys, Merck, Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, and Lilly; and has received grants from Janssen and Edwards Lifesciences. Dr. Nicolau has received speaker/consulting honoraria and/or research grant support from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. Dr. López-Sendón has received research grants from AstraZeneca, Lilly/Daiichi-Sankyo, GlaxoSmithKline, Pfizer, Novartis, and Servier; and has received honoraria from AstraZeneca, Lilly/Daiichi-Sankyo, Merck, and Sanofi. Dr. Dalby has received personal fees from AstraZeneca during the conduct of the study; and has received personal fees from Aspen, Bayer, Boehringer Ingelheim, DiscoveryHealth, Lilly, Novartis, Pfizer, Sanofi, and Servier outside of the submitted work. Dr. Aylward has received a research grant, has received honoraria for speaking, and served on the advisory board of AstraZeneca. Dr. Abola has received grants and modest personal/speaker fees from and served on the local advisory board for AstraZeneca during the conduct of the study; as an investigator in other ticagrelor trials has received modest personal fees as a member of the advisory board of and as a speaker for Pfizer; has received modest personal fees as speaker for Bayer, Boehringer Ingelheim, and Daiichi-Sankyo; and has received modest investigator fees from Bayer, Boehringer Ingelheim, Daiichi-Sankyo, and Population Health Research The association of concomitant PAD with an increased risk of ischemic events is complicated by the fact that PAD is also associated with an increased risk of bleeding (13) . There are many shared comorbidities that increase the risk of both PAD and bleeding, including age and renal dysfunction. In addition, it is possible that the diseased vasculature in PAD patients may be more prone to injury or procedural complications leading to bleeding. In trials of potent antithrombotic strategies for prevention in PAD, there have been significant increases in bleeding risk, particularly with full-dose anticoagulants (7, 8, 10, 14) . Table 1 ). The proportional hazards assumption was visually examined by scaled Schoenfeld residual plot, and the validity of this assumption was not violated. Efficacy analyses were performed on an intention-to-treat basis. Safety analyses included all patients who received at least 1 dose of study drug and included all events occurring after receipt of the first dose and within 7 days of the last dose of study drug. The prognostic accuracy of the models was compared using the area under the curve derived from receiver-operating characteristic curves (C-statistic) (17) . The ability of the model to enhance discrimination and correctly reclassify subjects was additionally tested with the integrated discrimination improvement and the category-free net reclassification improvement (18, 19) . Table 1) . Baseline characteristics in those with and without PAD at baseline are shown in Table 1 , and by treatment arm within the PAD group in Online Figure 1A) . Rates of the individual components of CV death, MI, or stroke, as well as all-cause mortality were also higher in patients with PAD ( Figure 1B) . The risk of MACE associated with PAD at baseline was highest in patients with a history of prior peripheral revascularization, followed by those with claudication but no history of revascularization, and patients with an abnormal ABI (#0.90) alone (Figure 2 ). Among patients with PAD, components of MALE, including peripheral revascularization, occurred in 9.2% of patients and ALI in 1.0%, whereas (as expected) these events occurred in <1% of patients without known PAD at randomization ( Figure 1B) . Overall, beyond PAD history, independent predictors of MALE at baseline were prior CABG, current smoking, hypertension, chronic obstructive pulmonary disease, and diabetes (Online Table 2 ). For the patients with known PAD, a prior CI: 1.01% to 1.91%) at baseline, although events were infrequent. Secondary bleeding outcomes by baseline PAD for both ticagrelor doses are shown in Table 2 .
Rates of intracranial hemorrhage and fatal bleeding in patients with PAD were low. Table 6 ) as well as when including amputation for any reason (Online Table 7) . site-reported; however, they were collected on a specific case report form page with instructions. Values are n, 3-year Kaplan-Meier (%), unless otherwise indicated.
Abbreviations as in Table 2 . 
